2417 Westport Dr, Norman, OK 73069 Phone (405) 701-2424

captionYou can effect change if you are bold, strong and positiveCaption


$24-Million Public-Private Partnership Expands Investigation of Parkinson's Disease

The Michael J. Fox Foundation (MJFF), the National Institutes of Health (NIH) and five life sciences companies today announced a public-private partnership to advance understanding, measurement and treatment of Parkinson's disease. The latest focus of the NIH Accelerating Medicines Partnership (AMP) model, this new AMP PD project will apply cutting-edge technologies to tease apart microscopic differences in the cells of people with Parkinson's disease (PD).

Read more


Nicole Jarvis's Oklahoma Winter Gala Snowballs into Success Year after Year

When Nicole Jarvis, 44, was diagnosed with Parkinson's disease (PD) in her late thirties, she immediately began searching for a way to get involved. As a physician, she was drawn to understanding the scientific side of the disease and her symptoms. Moreover, as a local Norman, Oklahoma resident, she was determined to raise the profile of Parkinson's in her community and to increase resources to support patients' quality of life -- particularly for the estimated 15,000 people with PD in her home state.

Read more


Community Tips for Parkinson's Disease Care Partners

When a loved one is diagnosed with Parkinson's disease (PD), spouses, children and close friends may find themselves transitioning into the role of a care partner. For many with Parkinson's, care partners are an integral part of their support system and care team. For care partners, this may bring questions about how best to support a loved one while maintaining other interests and responsibilities.

Read more


First LRRK2 Drug InN Clinical Trials, Company Files Public Offering

San Francisco-based Denali Therapeutics has raised nearly $250 million in its initial public offering, marking the largest biotech IPO of the year. In announcing terms of the IPO -- a major milestone in the life cycle of any company as it first offers stock options publicly, garnering capital for growth and expansion -- Denali shared it is testing a LRRK2 inhibitor drug in a small trial of control volunteers.

Read more


Parkinson's Protein Levels Stable over Year in Early Disease

Today researchers from the Parkinson's Progression Markers Initiative (PPMI) -- a landmark study to find measures of Parkinson's disease sponsored by The Michael J. Fox Foundation (MJFF) -- published the first results looking at protein levels in spinal fluid in a large, longitudinal cohort. They analyzed cerebrospinal fluid (CSF) from 173 people recently diagnosed with Parkinson's and 112 control volunteers collected at baseline (when they joined PPMI) and six- and 12-month follow-up.

Read more



Current Sponsors

View All Sponsors